Tyra Biosciences (TYRA)

Executive Summary

Tyra Biosciences is a clinical-stage precision medicine company leveraging its proprietary SNÅP platform to develop highly selective FGFR inhibitors designed to overcome treatment-emergent resistance and off-target toxicities. The lead candidate, dabogratinib (TYRA-300), is a next-generation FGFR3 inhibitor being evaluated in multiple indications, including achondroplasia (Phase 2) and urologic cancers such as urothelial carcinoma (Phase 1/2). Additionally, TYRA-430, a pan-FGFR inhibitor with a focus on FGFR2/4, is in a Phase 1 trial for FGFR-driven hepatocellular carcinoma. The early-stage pipeline also includes TYRA-200 for cholangiocarcinoma. Despite being in earlier clinical stages, the company's strong scientific foundation addresses significant unmet needs in FGFR-driven diseases. However, competition from approved FGFR inhibitors (e.g., erdafitinib, pemigatinib) and other pipeline candidates remains a key risk. Tyra's financial position, with a market cap of ~$2.1B, reflects optimism about its platform and first-in-class potential in achondroplasia. Near-term catalysts include initial Phase 2 data for TYRA-300 in achondroplasia and updated results from the Phase 1/2 urothelial carcinoma trial, which could provide early efficacy signals. The Phase 1/2 SURF301 trial in urothelial cancer is evaluating TYRA-300 in patients with FGFR3 alterations, and positive data could support accelerated development. The achondroplasia program is particularly de-risked by the use of an oral small molecule targeting a skeletal dysplasia, a market with high unmet need. Additionally, the Phase 1 trial for TYRA-430 in hepatocellular carcinoma is enrolling, with initial safety and pharmacokinetic data expected. Overall, Tyra Biosciences is poised for several value-driving milestones over the next 12–18 months.

Upcoming Catalysts (preview)

• H2 2026Interim Phase 2 data for TYRA-300 in achondroplasia60% success
• H2 2026Updated Phase 1/2 data for TYRA-300 in urothelial carcinoma (SURF301)50% success
• 2027Initial Phase 1 dose escalation data for TYRA-430 in hepatocellular carcinoma40% success